🚀 VC round data is live in beta, check it out!
Krka Valuation Multiples
Discover revenue and EBITDA valuation multiples for Krka and similar public comparables like Eisai Co., Aurobindo Pharma, Huadong Medicine, Nuvalent and more.
Krka Overview
About Krka
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, East Europe region, and Others. The company derives a majority of its revenue from the European Union.
Founded
1954
HQ
Employees
12.8K
Website
Sectors
Financials (LTM)
EV
$8B
Krka Financials
Krka reported last 12-month revenue of $2B and EBITDA of $658M.
In the same LTM period, Krka generated $658M in EBITDA and $479M in net income.
Revenue (LTM)
Krka P&L
In the most recent fiscal year, Krka reported revenue of $2B and EBITDA of $703M.
Krka expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | — | XXX | 57% | XXX | XXX | XXX |
| EBITDA | $658M | XXX | $703M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $479M | XXX | $478M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 20% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Krka Stock Performance
Krka has current market cap of $9B, and enterprise value of $8B.
Market Cap Evolution
Krka's stock price is $287.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8B | $9B | -0.2% | XXX | XXX | XXX | $15.79 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKrka Valuation Multiples
Krka trades at 3.2x EV/Revenue multiple, and 12.1x EV/EBITDA.
EV / Revenue (LTM)
Krka Financial Valuation Multiples
As of April 18, 2026, Krka has market cap of $9B and EV of $8B.
Equity research analysts estimate Krka's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Krka has a P/E ratio of 18.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV/Revenue | 3.2x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 12.1x | XXX | 11.3x | XXX | XXX | XXX |
| EV/EBIT | 14.7x | XXX | 14.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.7x | XXX | XXX | XXX |
| P/E | 18.2x | XXX | 18.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 15.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Krka Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Krka Margins & Growth Rates
Krka's revenue in the last 12 month grew by 4%.
Krka's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Krka's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Krka's rule of X is 39% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Krka Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | (3%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Krka Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Krka | XXX | XXX | XXX | XXX | XXX | XXX |
| Eisai Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Aurobindo Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Huadong Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Nuvalent | XXX | XXX | XXX | XXX | XXX | XXX |
| Vaxcyte | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Krka M&A Activity
Krka acquired XXX companies to date.
Last acquisition by Krka was on XXXXXXXX, XXXXX. Krka acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Krka
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKrka Investment Activity
Krka invested in XXX companies to date.
Krka made its latest investment on XXXXXXXX, XXXXX. Krka invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Krka
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Krka
| When was Krka founded? | Krka was founded in 1954. |
| Where is Krka headquartered? | Krka is headquartered in Slovenia. |
| How many employees does Krka have? | As of today, Krka has over 12K employees. |
| Is Krka publicly listed? | Yes, Krka is a public company listed on Ljubljana Stock Exchange. |
| What is the stock symbol of Krka? | Krka trades under KRKG ticker. |
| When did Krka go public? | Krka went public in 1997. |
| Who are competitors of Krka? | Krka main competitors are Eisai Co., Aurobindo Pharma, Huadong Medicine, Nuvalent. |
| What is the current market cap of Krka? | Krka's current market cap is $9B. |
| What is the current revenue of Krka? | Krka's last 12 months revenue is $2B. |
| What is the current revenue growth of Krka? | Krka revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Krka? | Current revenue multiple of Krka is 3.2x. |
| Is Krka profitable? | Yes, Krka is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Krka? | Krka's last 12 months EBITDA is $658M. |
| What is Krka's EBITDA margin? | Krka's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Krka? | Current EBITDA multiple of Krka is 12.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.